Dr. Barney Scott Graham (born 1953)

Wikipedia 🌐 Barney S. Graham

ASSOCIATIONS - People

ASSOCIATIONS - Companies and Institutions

ASSOCIATIONS - Events

  • Zika virus epidemic (2015-2016) ( Dr. barney Graham was one of the first people in the US health institutes to hear about a potential Zika outbreak in South America, in a July 2015 hallway conversation with a Brazilian doctor... see [HN01NN][GDrive] )

Saved Wikipedia (June 26, 2021) - "Barney S. Graham"

Source - [HK007H][GDrive]

Barney S. Graham is an American immunologist, virologist and clinical trials physician. He is the Deputy Director of the [The Vaccine Research Center] and the Chief of the Viral Pathogenesis Laboratory.

Early life and education

Graham attended Paola High School in Paola, Kansas, where he graduated as valedictorian in 1971 before enrolling at Rice University to major in biology. He earned a medical degree from the University of Kansas School of Medicine in 1979. Graham met his wife Cynthia Turner-Graham during medical school and they wished to complete residencies in the same community. He interviewed at Vanderbilt University and accepted a residency there while Turner-Graham was accepted at Meharry Medical College, both in Nashville, Tennessee.[1] Graham completed his internship, residency, two chief residencies, and infectious diseases fellowship at Vanderbilt.[2]

Career

By 1982, Graham was appointed chief resident[clarification needed] at Nashville General Hospital, where he treated Tennessee's first AIDS patient.[1] Following this, he was named to a chief residency at Vanderbilt University Medical Center,[3]where he led the first human trial on the AIDS vaccine.[4] The results of the trial found that the two experimental AIDS vaccines proved to yield the best immune response in patients.[5] During his time at Vanderbilt, Graham was simultaneously working on a Ph.D. in microbiology.[3]

Graham was elected a member of the American Society for Clinical Investigation in 1996.[6] In 2000, the National Institutes of Health (NIH) recruited him to create a vaccine evaluation clinic [The Vaccine Research Center], but he insisted on maintaining a research laboratory to focus on vaccines for three categories of respiratory viruses.[1] During the 2015–2016 Zika virus epidemic, Graham and Ted Pierson, chief of the Laboratory of Viral Diseases, collaborated to create a vaccine intended to prevent the Zika virus. Moving from inception to manufacturing in just three months, they began Phase 2 clinical trial in March 2017 to measure its effectiveness. In recognition of their efforts, they were finalists for the 2018 Promising Innovations Medal.[7]

Working alongside Jason McLellan, a structural biologist, they discovered that "adding two prolines to a key joint of a vaccine's spike protein could stabilize the structure's prefusion shape". This method would later be applied to the COVID-19 vaccine.[8] During the COVID-19 pandemic, Graham's laboratory partnered with Moderna to develop vaccine technology. He was a member of the research team that designed a spike protein to combat the virus. His research found that some virus proteins change shape after they break into a person's cells, leading to the design of a better vaccine against respiratory syncytial virus.[9][10]

Personal life

Graham is married to Cynthia Turner-Graham and they have three adult children together.[11]

References

External links


FEATURED MEMBER


2021-incirclexec-com-cynthia-turner-graham.pdf

https://drive.google.com/file/d/1aLAj99ScwJWS5ZQL6BTNV_ezgpJaW_CL/view?usp=sharing

2021-incirclexec-com-cynthia-turner-graham-img-1.jpg

https://drive.google.com/file/d/1wZMwf2U3qHXoAgFrR_SZMkVad9UHrNEe/view?usp=sharing


CYNTHIA TURNER-GRAHAM, M.D. – DISTINGUISHED PSYCHIATRIST

Rockville, MD — Cynthia Turner-Graham, M.D. is being recognized by Continental Who’s Who as a Distinguished Psychiatrist for her contributions in psychiatry as a healthcare administrator, direct service provider, and advocate, promoting high quality, accessible mental health services for all.

A Distinguished Fellow of the American Psychiatric Association, Dr. Turner-Graham has led an impressive career for over 20 years. She has established a reputation for outstanding contributions in the communities in which she has lived and the individuals whose lives have been enriched by the compassionate mental health services she provides. Motivated by her administrative and clinical experiences, she established ForSoundMind Enterprises, LLC, with a particular focus on enhancing the mental, physical and spiritual health of groups, families, and individuals. She excels in building on personal strengths and creating transformative life experiences. Through her health promotion workshops as well as in her practice, she provides services and programs that generate “sound mindedness” with the ultimate goal being to facilitate the development of more effective communication skills and emotional intelligence to construct more meaningful and satisfying lives. The satisfaction of bearing witness to the discovery of inner strength her patients could not previously see for themselves keeps her invigorated. Alongside her role as President and CEO of ForSoundMind Enterprises, Inc, she has worked in private and public settings where she takes a wholistic approach to the comprehensive treatment of individuals and families, providing both psychotherapies and psychotropic medication when indicated.

Dr. Turner-Graham’s academic achievements include a Bachelor of Science degree in Chemistry from Fisk University and a Doctor of Medicine degree from the University of Kansas after which she completed a residency in Psychiatry at Vanderbilt University School of Medicine. During the last months of her residency, she worked evenings in a community mental health center with children and teens. While starting a private practice, she increased her hours at the mental health center and became its first Medical Director. Additionally, during a period of organizational expansion in the 1990s, she became the Vice President of Medical Services, overseeing a staff of 80+ physicians and nurses spread throughout 26 counties in Middle Tennessee. Remaining abreast of the latest advancements in her field, Dr. Turner-Graham maintains active memberships in the American Psychiatric Association, the Washington Psychiatric Society where she serves on the board of directors, is President of the Suburban Maryland Psychiatric Society, and is President-elect of the Black Psychiatrists of America.

In her spare time, Dr. Turner-Graham enjoys exercising, meditating, writing, and reading. She also serves as the Mental Health Ministry Director at her church.

Dr. Turner-Graham is happily married to her husband, Barney S. Graham, M.D., Ph.D. They have three adult children and eight grandchildren. She dedicates this honorable recognition to her paternal grandfather, Roger Turner, who in 1920 had a bold vision of educational excellence and achievement for future generations. Abandoning the life he knew as a sharecropper and teacher in a one-room segregated school in Mississippi, Mr. Turner moved his family to a city where the dreams of higher education could become reality.

As a testament to her professional excellence, Dr. Turner-Graham has been named Professional of the Year in Psychiatry.

Approaching retirement, Dr. Turner-Graham plans to expand her public and motivational speaking to groups, organizations, and corporations generally centered on the issues of mental health promotion and mental illness prevention. As a self-proclaimed visionary, she strongly believes that more positive “vision casting” is needed to transform America into the best version of itself.


2019 (Dec 19) - NIH post : "NIH-Developed Zika Vaccine Improves Fetal Outcomes in Animal Model"

https://www.niaid.nih.gov/news-events/nih-developed-zika-vaccine-improves-fetal-outcomes-animal-model

2019-12-19-usa-gov-nih-developed-zika-vaccine-fetal-outcome-animal-model.pdf

https://drive.google.com/file/d/1Y2lkS1x_PoJEgml_8Pe0qkOLg_NEMpkz/view?usp=sharing

2019-12-19-usa-gov-nih-developed-zika-vaccine-fetal-outcome-animal-model-img-1.jpg

https://drive.google.com/file/d/1BjgIuZnMg9bus4LoQQWO_rnTVFdD_gzO/view?usp=sharing

An experimental Zika vaccine lowered levels of virus in pregnant monkeys and improved fetal outcomes in a rhesus macaque model of congenital Zika virus infection, according to a new study in Science Translational Medicine. The research was conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators from the University of California, Davis; Duke University; and the University of California, Los Angeles. NIAID scientists developed the experimental vaccine and currently are evaluating it in a Phase 2 human clinical trial. The vaccine uses a small circular piece of DNA, or plasmid, containing genes that encode Zika virus surface proteins to induce an immune response.

Zika virus is primarily transmitted to humans by Aedes mosquitoes; it also can be transmitted through sex. The virus can cause serious birth defects in babies born to mothers who become infected during pregnancy. Ideally, the authors note, a Zika vaccine would be given to adolescents and adults of childbearing age before pregnancy to prevent congenital Zika syndrome.

Large outbreaks of Zika virus in the Americas in 2015 and 2016 led to thousands of cases of congenital Zika syndrome, prompting NIAID scientists to quickly develop and begin clinical trials of the NIAID DNA Zika vaccine. While clinical trials can yield data on safety and how the vaccine performs in recipients, due to the diminished incidence of Zika, conducting a clinical trial that would determine the vaccine’s ability to prevent adverse fetal outcomes has been logistically difficult. Therefore, researchers developed a macaque model of congenital Zika syndrome to provide another way to evaluate the experimental vaccine.

Their study compared outcomes in 12 unvaccinated pregnant macaques and 13 macaques vaccinated before pregnancy. All macaques were exposed to Zika virus a total of three times during the first and second trimesters. Vaccinated animals had a significant reduction in the amount of Zika virus in the blood and in the length of time virus was detectable compared to unvaccinated animals. The vaccinated group was significantly less likely to transmit Zika virus to the fetus, whereas persistent Zika virus infection in unvaccinated macaques was associated with fetal infection. No cases of early fetal loss occurred in the vaccinated group, which also had no evidence of damage to either the placenta or the fetal brain.

The study suggests that sterilizing immunity—an immune response that prevents infection entirely, with no detectable virus—may not be required for significant protection against congenital Zika syndrome, according to the authors. They note that the ability of a vaccine to prevent persistent Zika virus infection may be an important consideration for future clinical research. Meanwhile, the animal model can be used to learn more about Zika virus transmission from mother to fetus and possible intervention strategies.

ARTICLE:

KV Rompay et al. DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Science Translational Medicine DOI: 10.1126/scitranslmed.aay2736 (2019).

WHO:

NIAID Director Anthony S. Fauci, M.D., is available to comment. Paper authors Barney S. Graham, M.D., Ph.D., deputy director of NIAID’s Vaccine Research Center, and Theodore C. Pierson, Ph.D., chief of NIAID’s Laboratory of Viral Diseases, are also available.

This research was funded by the NIAID Intramural Research Program and by the following NIH grants: R21AI129479-S, P510D11107, R21NS104692, R21HD090856, R01HD098389 and T32 CA009111.